You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
畢馬威威首發生物科技創新50報告 中國發展機遇前所未有
由畢馬威主辦,招商證券股份有限公司協辦,並聯合多位行業專家共同評選,第一屆畢馬威中國生物科技創新50報告發布,本次評選報告重點集中的領域包括生物製藥、細胞治療與基因治療、醫療器械、體外診斷、藥物研發等,其中生物製藥所佔比例最高;從地域上看,滬、杭、京、深位列前四,城市群集聚效應強勁。 畢馬威中國副主席江立勤表示,生物醫藥科技產業正快速由最具發展潛力的高技術產業向高技術支柱產業發展。中國人口老齡化帶來大健康消費不斷升級,相關醫藥監管新政的紅利逐步釋放,給生物科技發展帶來前所未有的發展機遇。 報告認為,當前頂層設計及規劃的完善助益了總體利好的創新政策環境。2017年發佈的《關於深化審評審批制度改革鼓勵藥品醫療器械創新的意見》,被視為藥品和醫療器械的審評審批改革的重要里程碑,為生物科技創新明確了發展方向。「十四五」規劃將創新作為新發展理念中的重中之重,進一步強化了中國科研領域的頂層規劃,中國生物科技創新企業將順勢而為,助力於實現新規劃中科技前沿、創新體系、創新產業及人民健康四個方面的戰略目標。 畢馬威中國生命科學行業主管合夥人于子龍指出,近年來中國獲批上市的創新藥總數、獲批的國產創新醫療器械數量顯著增加。中國在研發管線產品和首發上市新藥的數量方面,對全球的貢獻越來越大,成功進入全球研發領先梯隊;同時,醫療器械企業的專業授權數量自2016年以來也穩步增長。在上市後市場准入方面,國家醫保談判周期縮短、准入窗口增加,越來越多的創新藥物可以通過談判方式納入國家醫保目錄,也為創新藥物支付提供了更大的支持。 根據本次報告評選情況,華東區位於長三角城市群的企業佔比高達61%,可以看出長三角地區生物科技發展潛力非常強大;華北區,以京津冀為核心的企業在本次評選中佔比16%;華南區以粵港澳為核心區的企業在報告中,優勢也非常明顯,相關企業數量占比23%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account